U.S. V. Mccarthy & Hough, Transcript of Hearing on Validity of MDMA

Total Page:16

File Type:pdf, Size:1020Kb

U.S. V. Mccarthy & Hough, Transcript of Hearing on Validity of MDMA EXHIBIT 1 1 0C64MCC1 1 UNITED STATES DISTRICT COURT 1 SOUTHERN DISTRICT OF NEW YORK 2 ------------------------------x 2 3 UNITED STATES OF AMERICA 3 4 v. 09CR1136(WHP) 4 5 SEAN McCARTHY, 5 LARRY WARREN HOUGH, 6 Defendants. 6 7 ------------------------------x 7 8 New York, NY 8 December 6, 2010 9 10:10 a.m. 9 10 Before: 10 11 HON. WILLIAM H. PAULEY III 11 12 District Judge 12 13 APPEARANCES 13 14 PREET BHARARA 14 United States Attorney for the 15 Southern District of New York 15 DANIEL CHUNG 16 ELISHA KOBRE 16 Assistant United States Attorneys 17 17 MICHAEL SPORN 18 SCOTT MICHELMAN 18 JAY RORTY 19 Attorneys for Defendant McCarthy 19 20 JOHN C. MERINGOLO 20 Attorney for Defendant Hough 21 21 22 23 24 25 SOUTHERN DISTRICT REPORTERS, P.C. (212) 805-0300 2 0C64MCC1 1 (Case called) 2 THE COURT: Good morning, I note the presence of the 3 defendant Mr. McCarthy at counsel table and I note the presence 4 of Mr. Hough as well. This matter is on for a hearing. Are 5 the parties ready to proceed. 6 MR. CHUNG: The government is ready. 7 MR. RORTY: We are, your Honor. There are two 8 preliminary matters I would like to discuss. 9 THE COURT: Go ahead. 10 MR. RORTY: The government filed a letter with this 11 court Friday afternoon, that is December 3. I wanted to make 12 sure the court has received that letter. 13 THE COURT: I have. 14 MR. RORTY: On Mr. McCarthy's behalf, we filed a 15 pleading, a motion to exclude extrinsic evidence of the defense 16 expert's conduct yesterday afternoon, a motion electronically 17 filed with two affidavits, I wanted to make sure the court 18 received that document. 19 THE COURT: I have not seen that. So, if you would be 20 kind enough to hand a copy up, I would appreciate it. 21 (Pause) 22 THE COURT: I assume I can review this as we proceed 23 or during a recess, but we are not going to get to this matter 24 immediately. 25 MR. RORTY: I think that's probably appropriate given SOUTHERN DISTRICT REPORTERS, P.C. (212) 805-0300 3 0C64MCC1 1 that the court has not had a chance to review it. We are 2 prepared to take up the issue at any time the court feels is 3 appropriate. Perhaps after the break or before Dr. Halpern's 4 testimony would be the best time after the court has had a 5 chance to review our document. 6 THE COURT: That's fine. 7 You said there was another matter. 8 MR. RORTY: Before we call our first witness, I would 9 like a few minutes to give the court a road map of what we 10 think will occur over the next couple of days, an introduction 11 to Mr. McCarthy's evidence in this matter. 12 THE COURT: That's fine. 13 MR. RORTY: At our previous hearing the government 14 argued that there was no need for this proceeding because in 15 2001, the United States Sentencing Commission heard testimony 16 and took substantial evidence regarding the harms of MDMA. The 17 government at that point argued that that settled the issue of 18 whether a post-Kimbro policy variance might apply in this case. 19 That argument can now be dismissed because we are having this 20 hearing. The fact that the commission held proceedings cannot 21 control the issue. 22 The question before this court is whether or not the 23 conclusions drawn by the commission in 2001 are still valid. 24 If they are, then the offense level controls and the guidelines 25 apply. If those conclusions have been undermined by the decade SOUTHERN DISTRICT REPORTERS, P.C. (212) 805-0300 4 0C64MCC1 1 of science that has occurred since that hearing, we would 2 submit that a variance in this case is necessary and 3 appropriate. 4 As the court will recall in notes from the papers, 5 the commission based all of its findings resulting in the 6 offense level on a couple of key assumptions. First, that MDMA 7 is extremely neurotoxic, that it causes cell death. Second, 8 that MDMA is more harmful than cocaine in several respects. 9 If at the end of this hearing the court concludes that 10 the commission erred in those assumptions and reaching those 11 conclusions, then we would say that pursuant to Kimbro, a 12 variance is necessary and appropriate in this case. We would 13 be talking then not about whether the court should vary but how 14 far. If the commission got it wrong, if those assumptions are 15 false, then the offense level is not appropriate and the 16 sentence commensurate with that offense level should not be 17 imposed, there should be a variance. 18 We think based on Dr. Curran's, Dr. Halpern's, and 19 indeed on Dr. Parrott's and Dr. Hanson's, Mr. Hanson's 20 testimony, there will be some consensus that the commission got 21 it wrong and that the question is how far did they get it 22 wrong, how wrong were they, particularly about neurotoxicity 23 and cocaine. We will then at the end of the hearing be 24 discussing what is the harm of MDMA in relation to cocaine and 25 other drugs and how neurotoxic is it to the extent it is SOUTHERN DISTRICT REPORTERS, P.C. (212) 805-0300 5 0C64MCC1 1 neurotoxic, that it causes cell death. 2 The court will hear some scientific disagreement with 3 respect to the extent and nature of neurotoxicity and the harm 4 relative to cocaine. But I suspect that discussion will be 5 predicated on an understanding that the commission got it 6 wrong, that the extraordinary neurotoxicity found by the 7 commission has been disproved, and that MDMA is not more 8 harmful than cocaine. At the end of the hearing we will be 9 asking the court to vary and arguing that the extent of the 10 variance should find that MDMA is approximately as harmful as 11 marijuana. But we expect that the scope of that argument at 12 the conclusion of the hearing will simply be about the extent 13 of the necessary variance called for in this case. 14 We are now prepared to call Dr. Valerie Curran. 15 Mr. Michelman will conduct that examination. 16 THE COURT: Very well. 17 HELEN VALERIE CURRAN, 18 called as a witness by the Defendants, 19 having been duly sworn, testified as follows: 20 DIRECT EXAMINATION 21 BY MR. MICHELMAN: 22 Q. Could you please tell the court your current title. 23 A. I am currently professor of psychopharmacology at 24 University College, London. 25 Q. Could you describe your main job responsibilities in that SOUTHERN DISTRICT REPORTERS, P.C. (212) 805-0300 6 0C64MCC1 Curran - direct 1 role. 2 A. I am director of the clinical psychopharmacology unit. I 3 am an academic. I have students. I mainly do research. I 4 also am a clinical psychologist and a research lead at the 5 national health service, a series of clinics giving drug 6 treatment to addicts. 7 Q. Could you describe some of your professional associations 8 and activities? 9 A. Yes. I am a member of Council of British Association of 10 Psychopharmacology. I am a member of the U.K. Independent 11 Scientific Committee on Drugs. I am a member of several other 12 societies to do with addiction. I am also principal editor of 13 the major journal in the field, unfortunately also called 14 Psychopharmacology. 15 Q. Could you tell the court what degrees you hold. 16 A. I have a bachelor's and a master's degree from Cambridge 17 University and a PhD from London University and professional 18 qualifications from the British Psychological Society. 19 Q. Describe your area of research expertise. 20 A. My research concerns the cognitive and mood effects of 21 drugs acting on the brain. 22 Q. Tell us the sources of the funding for your research. 23 A. Yes. My current funding is mostly government, mainly the 24 Medical Research Council, also the Economic and Social Research 25 Council in the U.K. I also get money, small amounts of money SOUTHERN DISTRICT REPORTERS, P.C. (212) 805-0300 7 0C64MCC1 Curran - direct 1 from various charities, including the Beckley Foundation and 2 the Alcohol and Education Research Council. 3 Q. It sounds like the bulk of your funding is from the 4 government. 5 A. Yes, nearly all of it. 6 Q. Do you have any experience testifying in court? 7 A. I have only been in court twice, once with a mass 8 litigation for the crown against pharmaceutical companies 9 producing benzodiazepine, like Xanax and Valium, where a large 10 case was taken forward against companies that produced them, 11 and the second case was in the case of drug-assisted rape where 12 again I acted on behalf of prosecution. I have done a lot of 13 legal reports and I also sit on government committees such as 14 the Ministry of Defense Ethics Committee where my expertise on 15 drugs abuse is used. 16 Q. How long have you researched on MDMA? 17 A. MDMA, 14 years. 18 Q. How long have you researched on marijuana? 19 A. About 12 years. 20 Q. How long have you researched on ketamine? 21 A. On ketamine, 11 years.
Recommended publications
  • Neurotransmitter Resource Guide
    NEUROTRANSMITTER RESOURCE GUIDE Science + Insight doctorsdata.com Doctor’s Data, Inc. Neurotransmitter RESOURCE GUIDE Table of Contents Sample Report Sample Report ........................................................................................................................................................................... 1 Analyte Considerations Phenylethylamine (B-phenylethylamine or PEA) ................................................................................................. 1 Tyrosine .......................................................................................................................................................................................... 3 Tyramine ........................................................................................................................................................................................4 Dopamine .....................................................................................................................................................................................6 3, 4-Dihydroxyphenylacetic Acid (DOPAC) ............................................................................................................... 7 3-Methoxytyramine (3-MT) ............................................................................................................................................... 9 Norepinephrine ........................................................................................................................................................................
    [Show full text]
  • Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression
    Neuropsychopharmacology (2003) 28, 1387–1399 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Perspective Emerging Evidence for a Central Epinephrine-Innervated a1- Adrenergic System that Regulates Behavioral Activation and is Impaired in Depression ,1 1 1 1 1 Eric A Stone* , Yan Lin , Helen Rosengarten , H Kenneth Kramer and David Quartermain 1Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA Currently, most basic and clinical research on depression is focused on either central serotonergic, noradrenergic, or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain a1B-adrenoceptors innervated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems in parallel and plays a critical role in depression. The present review covers the evidence for this system and includes findings that brain a -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups 1 or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and a are restored by a number of antidepressants. This ‘EPI- 1 system’ may therefore represent a new target system for this disorder. Neuropsychopharmacology (2003) 28, 1387–1399, advance online publication, 18 June 2003; doi:10.1038/sj.npp.1300222 Keywords: a1-adrenoceptors; epinephrine; motor activity; depression; inactivity INTRODUCTION monoaminergic systems. This new system appears to be impaired during stress and depression and thus may Depressive illness is currently believed to result from represent a new target for this disorder.
    [Show full text]
  • Neurotransmitters-Drugs Andbrain Function.Pdf
    Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Edited by R. A. Webster Department of Pharmacology, University College London, UK JOHN WILEY & SONS, LTD Chichester Á New York Á Weinheim Á Brisbane Á Singapore Á Toronto Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Copyright # 2001 by John Wiley & Sons Ltd. Bans Lane, Chichester, West Sussex PO19 1UD, UK National 01243 779777 International ++44) 1243 779777 e-mail +for orders and customer service enquiries): [email protected] Visit our Home Page on: http://www.wiley.co.uk or http://www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P0LP,UK, without the permission in writing of the publisher. Other Wiley Editorial Oces John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012, USA WILEY-VCH Verlag GmbH, Pappelallee 3, D-69469 Weinheim, Germany John Wiley & Sons Australia, Ltd.
    [Show full text]
  • 2-Phenylethylamine and Methamphetamine Enhance the Spinal Monosynaptic Reflex by Releasing Noradrenaline from the Terminals of Descending Fibers
    Japan. J. Pharmacol. 55, 359-366 (1991) 359 2-Phenylethylamine and Methamphetamine Enhance the Spinal Monosynaptic Reflex by Releasing Noradrenaline from the Terminals of Descending Fibers Hideki Ono, Hiroyuki Ito and Hideomi Fukuda' Departmentof Toxicologyand Pharmacology,Faculty of Pharmaceutical Sciences, TheUniversity of Tokyo,Hongo 7-3-1, Bunkyo-ku, Tokyo 113, Japan 'Departmentof Pharmacology, Collegeof Pharmacy,Nihon University, 7-7-1Narashinodai, Funabashi, Chiba 274, Japan ReceivedJuly 28, 1990 AcceptedDecember 27, 1990 ABSTRACT Experiments were performed on spinalized rats transected at C1. In travenous administration of 2-phenylethylamine-HC1 (PEA-HC1) (0.3 and 1 mg/kg, i.v.) and methamphetamine-HC1 (MAP-HC1) (0.1 and 0.3 mg/kg, i.v.) increased the amplitude of the monosynaptic reflex (MSR). The increase of the MSR caused by PEA and MAP was antagonized by prazosin-HC1 and abolished by the pretreatment with reserpine (i.p.) and 6-hydroxydopamine (intracisternally, 14 days previously). A dopamine D, antagonist, SK&F 83566-HBr (0.01 mg/kg, i.v. ), and a D2 antagonist, YM-09151-2 (0.3 mg/kg, i.v.), did not antagonize the increasing effects produced by PEA and MAP. An inhibitor of type-B monoamine oxidase, (-)deprenyl-HC1 (1 mg/kg, i.v.), prolonged the effect of PEA but not that of MAP, suggesting that PEA alone, and not its metabolites, enhanced the MSR. These results suggest that PEA and MAP increase the amplitude of the MSR by releasing noradrenaline from the ter minals of descending noradrenergic fibers, and that PEA, an endogenous trace amine, has a mechanism of action similar to that of MAP.
    [Show full text]
  • Tyramine and Amyloid Beta 42: a Toxic Synergy
    biomedicines Article Tyramine and Amyloid Beta 42: A Toxic Synergy Sudip Dhakal and Ian Macreadie * School of Science, RMIT University, Bundoora, VIC 3083, Australia; [email protected] * Correspondence: [email protected]; Tel.: +61-3-9925-6627 Received: 5 May 2020; Accepted: 27 May 2020; Published: 30 May 2020 Abstract: Implicated in various diseases including Parkinson’s disease, Huntington’s disease, migraines, schizophrenia and increased blood pressure, tyramine plays a crucial role as a neurotransmitter in the synaptic cleft by reducing serotonergic and dopaminergic signaling through a trace amine-associated receptor (TAAR1). There appear to be no studies investigating a connection of tyramine to Alzheimer’s disease. This study aimed to examine whether tyramine could be involved in AD pathology by using Saccharomyces cerevisiae expressing Aβ42. S. cerevisiae cells producing native Aβ42 were treated with different concentrations of tyramine, and the production of reactive oxygen species (ROS) was evaluated using flow cytometric cell analysis. There was dose-dependent ROS generation in wild-type yeast cells with tyramine. In yeast producing Aβ42, ROS levels generated were significantly higher than in controls, suggesting a synergistic toxicity of Aβ42 and tyramine. The addition of exogenous reduced glutathione (GSH) was found to rescue the cells with increased ROS, indicating depletion of intracellular GSH due to tyramine and Aβ42. Additionally, tyramine inhibited the respiratory growth of yeast cells producing GFP-Aβ42, while there was no growth inhibition when cells were producing GFP. Tyramine was also demonstrated to cause increased mitochondrial DNA damage, resulting in the formation of petite mutants that lack respiratory function.
    [Show full text]
  • Selegiline) in Monkeys*
    Intravenous self-administration studies with /-deprenyl (selegiline) in monkeys* /-Deprenyl and its stereoisomer d-deprenyl did not maintain intravenous self-administration behavior in rhesus monkeys. In contrast, /-methamphetamine, the major metabolite of /-deprenyl, as well as the baseline drug, cocaine, maintained high rates of intravenous self-administration behavior. Treatment with /-deprenyl doses up to 1.0 mg/kg before self-administration sessions failed to alter self-administra- tion of either cocaine or /-methamphetamine. Thus /-deprenyl did not appear to have cocaine- or meth- amphetamine-like reinforcing properties in monkeys and was ineffective in altering established patterns of psychomotor-stimulant self-administration behavior. These results support clinical findings that de- spite long-term use of /-deprenyl for the treatment of Parkinson's disease by large numbers of patients, no instances of abuse have been documented. /-Deprenyl has recently been suggested as a potential med- ication for the treatment of various types of drug abuse, including cocaine abuse, but its failure to pro- duce selective effects in decreasing cocaine or methamphetamine self-administration behavior in the present experiments makes such an application seem unlikely. (CLIN PHARMACOL THER 1994;56:774-80.) Gail D. Winger, PhD,a Sevil Yasar, MD,b'd'e S. Steven Negus, PhD,a and Steven R. Goldberg, pIli/i d'e Ann Arbor, Mich., and Baltimore, Md. From the 'Department of Pharmacology, University of Michigan /-Deprenyl (selegiline) has been known for several
    [Show full text]
  • 212102Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212102Orig1s000 OTHER REVIEW(S) Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research | Office of Surveillance and Epidemiology (OSE) Epidemiology: ARIA Sufficiency Date: June 29, 2020 Reviewer: Silvia Perez-Vilar, PharmD, PhD Division of Epidemiology I Team Leader: Kira Leishear, PhD, MS Division of Epidemiology I Division Director: CAPT Sukhminder K. Sandhu, PhD, MPH, MS Division of Epidemiology I Subject: ARIA Sufficiency Memo for Fenfluramine-associated Valvular Heart Disease and Pulmonary Arterial Hypertension Drug Name(s): FINTEPLA (Fenfluramine hydrochloride, ZX008) Application Type/Number: NDA 212102 Submission Number: 212102/01 Applicant/sponsor: Zogenix, Inc. OSE RCM #: 2020-953 The original ARIA memo was dated June 23, 2020. This version, dated June 29, 2020, was amended to include “Assess a known serious risk” as FDAAA purpose (per Section 505(o)(3)(B)) to make it consistent with the approved labeling. The PMR development template refers to the original memo, dated June 23, 2020. Page 1 of 13 Reference ID: 46331494640015 EXECUTIVE SUMMARY (place “X” in appropriate boxes) Memo type -Initial -Interim -Final X X Source of safety concern -Peri-approval X X -Post-approval Is ARIA sufficient to help characterize the safety concern? Safety outcome Valvular Pulmonary heart arterial disease hypertension (VHD) (PAH) -Yes -No X X If “No”, please identify the area(s) of concern. -Surveillance or Study Population X X -Exposure -Outcome(s) of Interest X X -Covariate(s) of Interest X X -Surveillance Design/Analytic Tools Page 2 of 13 Reference ID: 46331494640015 1.
    [Show full text]
  • HUK+Adult+FW1920+Catalogue+-+
    Saving You By (author) Charlotte Nash Sep 17, 2019 | Paperback $24.99 | Three escaped pensioners. One single mother. A road trip to rescue her son. The new emotionally compelling page-turner by Australia's Charlotte Nash In their tiny pale green cottage under the trees, Mallory Cook and her five-year- old son, Harry, are a little family unit who weather the storms of life together. Money is tight after Harry's father, Duncan, abandoned them to expand his business in New York. So when Duncan fails to return Harry after a visit, Mallory boards a plane to bring her son home any way she can. During the journey, a chance encounter with three retirees on the run from their care home leads Mallory on an unlikely group road trip across the United States. 9780733636479 Zadie, Ernie and Jock each have their own reasons for making the journey and English along the way the four of them will learn the lengths they will travel to save each other - and themselves. 384 pages Saving You is the beautiful, emotionally compelling page-turner by Charlotte Nash, bestselling Australian author of The Horseman and The Paris Wedding. Subject If you love the stories of Jojo Moyes and Fiona McCallum you will devour this FICTION / Family Life / General book. 'I was enthralled... Nash's skilled storytelling will keep you turning pages until Distributor the very end.' FLEUR McDONALD Hachette Book Group Contributor Bio Charlotte Nash is the bestselling author of six novels, including four set in country Australia, and The Paris Wedding, which has been sold in eight countries and translated into multiple languages.
    [Show full text]
  • British Film and TV Since 1960 COM FT 316 (Core Course)
    British Film and TV Since 1960 COM FT 316 (Core Course) Instructor Information Names Ms Kate Domaille; Dr Christine Fanthome Course Day and Meeting Time [Weekdays], [time] Course Location [Name] Room, 43 Harrington Gardens, SW7 4JU BU Telephone 020 7244 6255 Email Addresses [email protected]; [email protected] Office Hours By appointment Course Description In this course you will learn how British film and television has evolved from the 1960s to the present day You will undertake a series of case studies of British film and television genres and examine how the aesthetics, audience expectations and production conventions have changed over time You will develop a deep set of analytic skills for appreciating the evolution of British film and television The course provides opportunities to appreciate the specific evolution of film and television in the British context from the 1960s to the present day through the study of production conventions, representation and audiences. A close focus is placed on the development of film and television through an examination of industry movement and changing audience expectations over time. The course offers opportunities to analyse and evaluate social change through the medium of film and television. Subjects covered in individual sessions include comedy, crime, fantasy, art film and TV, youth culture, heritage drama, the ethics and logistics of filming in public spaces, documentary and social realism, and new documentary which will encompass reality TV and citizen journalism. Course Objectives On completion of the course, the successful student will show evidence of being able to: interpret film or television texts in terms of their understanding of the cultural contexts in which those works were created.
    [Show full text]
  • Archery for All the Real Benefits of Inclusivity Berkshire Archery Association Hidden History Brought to Light
    Official Magazine of Archery GB SUMMER 2021 | £4.95 BRITISH 3D Championships Rovers return to Pentref Archery for all The real benefits of inclusivity Berkshire Archery Association Hidden history brought to light SPECIAL Preparing for REPORT The Game Fair Discounted entry offer for AGB members Ragley Hall, 23-25 July TOKYOINTERNATIONAL JUDGES TALK THROUGH THEIR ROLES INSIDE: Compound • Getting archery-fit • Kit care • Griffin vane giveaway 2021 new MXT-10 www.wiawis.com l www.win-archery.com 2021 new META DX 2021 new ACS EL -- TRUETRUE- - SMOOTHNESS! SMOOTHNESS! MOSTMOST STABILITYSTABILITY &ACCURACY!&ACCURACY! -- BESTBEST SHOOTINGSHOOTING FEELING!FEELING! SUMMER 46 2021 NEWS/FEATURES News 06 A joyful return to the range, Big Reopening report, Big Weekend RIGHT: plans, new AGB strategy details, Day in the club round-up and more life of our RDO Mailbag 76 34 Have your say 58 Club Spotlight 36 Bowbrook Archers on their latest achievements History 38 The way we wore – clothing changes on the field Judge and jury ARCHERY GB Three international judges talk 40 through their roles ahead of the Day in the life Tokyo Games 58 Meet Toby Andrews, Regional Archery for all PRACTICAL Development Officer 46 A look at the sport’s accessibility Rule changes as told by the archers who know Latest updates How to 33 British 3D 62 Run a beginners’ course Directory Championships How to get in touch 52 Return to sport 80 Wet weekend in Wales went Chartered physiotherapist down a storm 66 Nicky Hunt on how to Berkshire Archery safely rebuild your form 40 55 Association
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. University Microfilms International A Bell & Howell Information C om pany 300 North Z eeb Road. Ann Arbor. Ml 48106-1346 USA 313/761-4700 800 521-0600 Order Number 9120692 Part 1. Synthesis of fiuorinated catecholamine derivatives as potential adrenergic stimulants and thromboxane A 2 antagonists. Part 2.
    [Show full text]
  • English Folk Traditions and Changing Perceptions About Black People in England
    Trish Bater 080207052 ‘Blacking Up’: English Folk Traditions and Changing Perceptions about Black People in England Submitted for the degree of Master of Philosophy by Patricia Bater National Centre for English Cultural Tradition March 2013 This work is licensed under the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ or send a letter to Creative Commons, 444 Castro Street, Suite 900, Mountain View, California, 94041, USA. Trish Bater 080207052 2 Abstract This thesis investigates the custom of white people blacking their faces and its continuation at a time when society is increasingly aware of accusations of racism. To provide a context, an overview of the long history of black people in England is offered, and issues about black stereotypes, including how ‘blackness’ has been perceived and represented, are considered. The historical use of blackface in England in various situations, including entertainment, social disorder, and tradition, is described in some detail. It is found that nowadays the practice has largely been rejected, but continues in folk activities, notably in some dance styles and in the performance of traditional (folk) drama. Research conducted through participant observation, interview, case study, and examination of web-based resources, drawing on my long familiarity with the folk world, found that participants overwhelmingly believe that blackface is a part of the tradition they are following and is connected to its past use as a disguise. However, although all are aware of the sensitivity of the subject, some performers are fiercely defensive of blackface, while others now question its application and amend their ‘disguise’ in different ways.
    [Show full text]